DNA Origami Vaccine Nanostructure for Tumor Antigen Presentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Cancer vaccines face challenges such as safety concerns, poor immunogenicity, immune suppression by tumors, and tumor antigen heterogeneity, leading to suboptimal immune responses.
Innovation Solution
A DNA origami nanostructure is developed with a rod shape formed by scaffold and staple strands, electrostatically attached peptide antigens, and conjugated with adjuvant molecules, targeting dendritic cells for enhanced immune activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional tumor vaccines are used, then safety concerns and poor immunogenicity are addressed, but suboptimal immune responses occur due to tumor antigen heterogeneity and immune suppression
Solution Approach 1:
The vaccine system is segmented into distinct functional modules: DNA origami nanostructure as carrier, peptide antigens as immunogenic components, and adjuvant molecules as immune stimulators. This segmentation allows each component to be optimized independently while maintaining overall system efficacy, resolving the contradiction between reliable immune response and formulation complexity.
Solution Approach 2:
The peptide antigens and adjuvant molecules are nested within the DNA origami nanostructure through electrostatic interactions. This nesting approach integrates multiple immune-regulating functions into a single unified vaccine particle, improving immune response reliability while simplifying the overall vaccine formulation and administration.
2Reliability
If multiple immune regulating functions are integrated, then robust tumor-specific immunogenicity is achieved, but device complexity increases
Solution Approach 1:
Multiple immune-regulating functions (antigen presentation, adjuvant activity, dendritic cell targeting) are merged into a single DNA origami nanostructure. This consolidation achieves robust tumor-specific immunogenicity while maintaining a relatively simple overall device architecture based on self-assembled DNA strands, resolving the contradiction between functional integration and device complexity.
Solution Approach 2:
The DNA origami nanostructure serves multiple functions simultaneously: it acts as a carrier for peptide antigens, provides electrostatic interactions for adjuvant molecules, enables targeting of dendritic cells, and facilitates antigen presentation. This multi-functionality achieves robust immunogenicity without requiring separate complex delivery systems for each function.
3Reliability
If peptide antigens are electrostatically attached to DNA nanostructure, then antigen presentation is enhanced, but manufacturing precision requirements increase
Solution Approach 1:
The peptide antigens are attached to the DNA origami nanostructure through electrostatic interactions between positively charged amino acids on the peptide and negatively charged DNA phosphodiester backbone. This self-assembling process occurs spontaneously under physiological conditions, enhancing antigen presentation efficiency while eliminating the need for complex manufacturing controls to achieve precise attachment density.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The DNA origami nanostructure enhances antigen presentation and T cell activation, providing robust tumor-specific immunogenicity and improved vaccine efficacy.
Implementation Method 1
a peptide antigen is attached to the DNA of the nanostructure by electrostatic interaction
Data Source
AI summary
Disclosed herein is a vaccine device that involves a DNA origami nanostructure formed from a plurality of scaffold strands and a plurality of staple strands assembled into a rod shape, wherein a peptide antigen is attached to the DNA of the nanostructure by electrostatic interaction. Also disclosed herein is a method for vaccinating a subject that involves administering to the subject a therapeutically effective amount of a vaccine device disclosed herein.